CBS News Staffers on the Verge of Revolt If This Person Is Hired
As Puerto Ricans Call for Independence Their Dreams Are Blocked By Their Chief...
President Trump Closes the Overton Window
The Fake Stream Media’s Pervasive Assault on Black America
Mamdani: More Continuation Than Aberration for New York
President Trump Is Bringing the Spirit of Sports Back to America
Money, Power and Transgender Ideology
Cleaning Up the Swamp Is a Full-Time Job for Trump
Iran's Mullahs Staring Into the Abyss
The Party of Losers Is Not Funny
The Enduring Lie of Socialism
DOJ: Minnesota Duo Orchestrated Kidnappings, Bombings in Africa
Michigan Woman Indicted for Smuggling Illegal Aliens, Children, Across the Northern Border
Tennessee Joins 25-State Coalition Defending Second Amendment Rights for Travelers
DOD Calls Out 'Highly Provocative' Move by Venezuela
Tipsheet

U.S. Buys 10 Million Treatment Courses of Pfizer’s COVID-19 Antiviral Pill

AP Photo/Virgina Mayo

Pharmaceutical corporation Pfizer announced on Thursday that the United States government will pay $5.29 billion for 10 million treatment courses of its experimental antiviral pill against the Wuhan coronavirus.

Advertisement

The pill, PAXLOVID, will be delivered by Pfizer beginning later this year and concluding in 2022, the company’s press release states. It notes that pricing for PAXLOVID “is based on the principles of advance commitment, volume, equity, and affordability.” Pfizer has also entered into advance purchase agreements with several other countries.

“We were thrilled with the recent results of our Phase 2/3 interim analysis, which showed overwhelming efficacy of PAXLOVID in reducing the risk of hospitalization among high-risk patients treated within three days of symptom onset by almost 90% and with no deaths, and are pleased the U.S. government recognizes this potential,” said Albert Bourla, Pfizer’s chairman and chief executive officer in a statement. “It is encouraging to see a growing understanding of the valuable role that oral investigational therapies may play in combatting [sic] COVID-19, and we look forward to continuing discussions with governments around the world to help ensure broad access for people everywhere.”

Advertisement

As I covered in September, Pfizer-BioNTech announced that they were in mid-to-late stage trails to test an oral drug designed to fight COVID-19. This month, findings from studies conducted by the company showed that PAXLOVID cut the risk of COVID-19 hospitalizations and death by 89 percent. 

In October, a New Jersey-based pharmaceutical company, Merck. Along with their partner Ridgeback Biotherapeutics, requested approval from the Food and Drug Administration (FDA) for a COVID-19 fighting pill.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement